A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in Interleukin 6 (IL-6), C-reactive Protein (CRP), Leptin, Transforming growth factor beta (TGF-beta), and Interferon (INF) gamma.
Inclusion Criteria:
Histologically confirmed diagnosis of RCC
Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
Metastatic Measurable disease, as defined by RECIST 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
Hematological:
Renal:
Hepatic:
Exclusion Criteria: